Glenmark Life Sciences Ltd - GLENMARK LIFE Share Price

Sector: Pharmaceuticals | ISIN: INE03Q201024
₹ 800.00 (1.13%) icon16 Apr, 2024, 12:00:00 AM

Glenmark Life Sciences Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 4/16/2024 12:00:00 AM

    ₹ 800 8.90 1.13
  • Open
  • ₹ 791
  • Prev. Close
  • ₹ 791.1
  • Turnover(Lac.)
  • ₹ 693
  • Day's High
  • ₹ 809
  • Day's Low
  • ₹ 767.05
  • 52 Week's High
  • ₹ 906
  • 52 Week's Low
  • ₹ 411.05
  • Book Value
  • ₹ 204.95
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 9,802.17
  • P/E
  • 18.86
  • EPS
  • 42.38
  • Divi. Yield
  • 5.26

Glenmark Life Sciences Ltd Corporate Actions

Glenmark Life Sciences Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Glenmark Life Sciences Ltd SHAREHOLDING SNAPSHOT
17 April , 2024 | 08:20 AM

PROMOTER - TOTAL82.85%

Indian: 82.85%

Foreign: 0%

NON-PROMOTER - TOTAL 17.15%

Institutions: 5.31%

Non-Institutions: 11.84%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Glenmark Life Sciences Ltd FINANCIALS

No Data Available To Display Chart

Glenmark Life Sciences Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Glenmark Life Sciences Ltd

  • Management Info Not Found
  • Summary

    The company was incorporated as Zorg Laboratories Private Limited, a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune (RoC). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019.The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The companys R&D facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh.During the year 2018-19, the company allotted 4,50,090 Equity Shares of Rs. 10/- each on the conversion of loan given to Director. During the year, 15,00,000... Read More


    Reports by Glenmark Life Sciences Ltd


    Reports by Glenmark Life Sciences Ltd

    Company FAQ

    No Record Found